Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Sexually Transmitted Diseases

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 69 articles:
HTML format



Single Articles


    September 2019
  1. YOSHIDA EJ, Luu M, Mallen-St Clair J, Mita AC, et al
    Stage I HPV-positive oropharyngeal cancer: Should all patients receive similar treatments?
    Cancer. 2019 Sep 19. doi: 10.1002/cncr.32501.
    PubMed     Abstract available


    July 2019
  2. PRINTZ C
    HPV infections most often linked to cervical cancer have declined.
    Cancer. 2019;125:2336-2337.
    PubMed    


    May 2019
  3. PRINTZ C
    Culturally tailored intervention increases HPV vaccination rates among Asian American adolescents.
    Cancer. 2019;125:1583.
    PubMed    


  4. PRINTZ C
    Cervical cancer self-sampling tests could improve access.
    Cancer. 2019;125:1583.
    PubMed    


  5. LIN TA, Garden AS, Elhalawani H, Elgohari B, et al
    Radiographic retropharyngeal lymph node involvement in HPV-associated oropharyngeal carcinoma: Patterns of involvement and impact on patient outcomes.
    Cancer. 2019;125:1536-1546.
    PubMed     Abstract available


    April 2019
  6. ROLLO F, Pichi B, Benevolo M, Giuliani M, et al
    Oral testing for high-risk human papillomavirus DNA and E6/E7 messenger RNA in healthy individuals at risk for oral infection.
    Cancer. 2019 Apr 29. doi: 10.1002/cncr.32152.
    PubMed     Abstract available


  7. TIAN S, Switchenko JM, Jhaveri J, Cassidy RJ, et al
    Survival outcomes by high-risk human papillomavirus status in nonoropharyngeal head and neck squamous cell carcinomas: A propensity-scored analysis of the National Cancer Data Base.
    Cancer. 2019 Apr 23. doi: 10.1002/cncr.32115.
    PubMed     Abstract available


  8. LI K, Li Q, Song L, Wang D, et al
    The distribution and prevalence of human papillomavirus in women in mainland China.
    Cancer. 2019;125:1030-1037.
    PubMed     Abstract available


    March 2019
  9. FAKHRY C, Zhang Q, Gillison ML, Nguyen-Tan PF, et al
    Validation of NRG oncology/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer: Implications for risk-based therapeutic intensity trials.
    Cancer. 2019 Mar 26. doi: 10.1002/cncr.32025.
    PubMed     Abstract available


  10. BEITLER JJ, Switchenko JM, Dignam JJ, McDonald MW, et al
    Smoking, age, nodal disease, T stage, p16 status, and risk of distant metastases in patients with squamous cell cancer of the oropharynx.
    Cancer. 2019;125:704-711.
    PubMed     Abstract available


  11. FARAJI F, Rettig EM, Tsai HL, El Asmar M, et al
    The prevalence of human papillomavirus in oropharyngeal cancer is increasing regardless of sex or race, and the influence of sex and race on survival is modified by human papillomavirus tumor status.
    Cancer. 2019;125:761-769.
    PubMed     Abstract available


    January 2019
  12. FROBERG M, Ostensson E, Belkic K, Ostrbenk A, et al
    Impact of the human papillomavirus status on the development of high-grade cervical intraepithelial neoplasia in women negative for intraepithelial lesions or malignancy at the baseline: A 9-year Swedish nested case-control follow-up study.
    Cancer. 2019;125:239-248.
    PubMed     Abstract available


  13. WINDON MJ, D'Souza G, Faraji F, Troy T, et al
    Priorities, concerns, and regret among patients with head and neck cancer.
    Cancer. 2019 Jan 15. doi: 10.1002/cncr.31920.
    PubMed     Abstract available


  14. BEESLEY LJ, Hawkins PG, Amlani LM, Bellile EL, et al
    Individualized survival prediction for patients with oropharyngeal cancer in the human papillomavirus era.
    Cancer. 2019;125:68-78.
    PubMed     Abstract available


    December 2018
  15. PRINTZ C
    High-risk human papillomavirus test a good option for cervical cancer screening.
    Cancer. 2018;124:4591.
    PubMed    


  16. PRINTZ C
    Human papillomavirus testing may detect cervical precancer better than Papanicolaou testing.
    Cancer. 2018;124:4430-4431.
    PubMed    


    November 2018
  17. EYTAN DF, Blackford AL, Eisele DW, Fakhry C, et al
    Prevalence of comorbidities and effect on survival in survivors of human papillomavirus-related and human papillomavirus-unrelated head and neck cancer in the United States.
    Cancer. 2018 Nov 16. doi: 10.1002/cncr.31800.
    PubMed     Abstract available


    October 2018
  18. ORTIZ AP, Engels EA, Nogueras-Gonzalez GM, Colon-Lopez V, et al
    Disparities in human papillomavirus-related cancer incidence and survival among human immunodeficiency virus-infected hispanics living in the United States.
    Cancer. 2018 Oct 22. doi: 10.1002/cncr.31702.
    PubMed     Abstract available


  19. THAM T
    Human papillomavirus and World Health Organization type III nasopharyngeal carcinoma: Multicenter study from an endemic area in Southern China.
    Cancer. 2018 Oct 21. doi: 10.1002/cncr.31819.
    PubMed    


  20. CHAN JYW, Huang WB, Liu DL
    Reply to Human papillomavirus and World Health Organization type III nasopharyngeal carcinoma: multicenter study from an endemic area in Southern China.
    Cancer. 2018 Oct 21. doi: 10.1002/cncr.31815.
    PubMed    


    May 2018
  21. XIAO C, Beitler JJ, Higgins KA, Glazer T, et al
    Associations among human papillomavirus, inflammation, and fatigue in patients with head and neck cancer.
    Cancer. 2018 May 9. doi: 10.1002/cncr.31537.
    PubMed     Abstract available


    April 2018
  22. TOTA JE, Engels EA, Madeleine MM, Clarke CA, et al
    Risk of oral tongue cancer among immunocompromised transplant recipients and human immunodeficiency virus-infected individuals in the United States.
    Cancer. 2018 Apr 12. doi: 10.1002/cncr.31359.
    PubMed     Abstract available


    January 2018
  23. RAZZAGHI H, Saraiya M, Thompson TD, Henley SJ, et al
    Five-year relative survival for human papillomavirus-associated cancer sites.
    Cancer. 2018;124:203-211.
    PubMed     Abstract available


    December 2017
  24. BALTZELL KA, Shen HM, Krishnamurty S, Sison JD, et al
    Bovine leukemia virus linked to breast cancer but not coinfection with human papillomavirus: Case-control study of women in Texas.
    Cancer. 2017 Dec 20. doi: 10.1002/cncr.31169.
    PubMed     Abstract available


  25. PRINTZ C
    Women who undergo HPV testing receive earlier detection and treatment of cervical precancers.
    Cancer. 2017;123:4751.
    PubMed    


  26. DAHLSTROM KR, Anderson KS, Field MS, Chowell D, et al
    Diagnostic accuracy of serum antibodies to human papillomavirus type 16 early antigens in the detection of human papillomavirus-related oropharyngeal cancer.
    Cancer. 2017;123:4886-4894.
    PubMed     Abstract available


    November 2017
  27. LANG KUHS KA, Kreimer AR, Trivedi S, Holzinger D, et al
    Human papillomavirus 16 E6 antibodies are sensitive for human papillomavirus-driven oropharyngeal cancer and are associated with recurrence.
    Cancer. 2017;123:4382-4390.
    PubMed     Abstract available


  28. PRINTZ C
    First person: Maura L. Gillison, MD, PhD: The researcher who found the link between the human papillomavirus and head and neck cancers continues to lead new discoveries in the field.
    Cancer. 2017;123:4307.
    PubMed    


    October 2017
  29. HUANG WB, Chan JYW, Liu DL
    Human papillomavirus and World Health Organization type III nasopharyngeal carcinoma: Multicenter study from an endemic area in Southern China.
    Cancer. 2017 Oct 26. doi: 10.1002/cncr.31031.
    PubMed     Abstract available


  30. GLEBER-NETTO FO, Zhao M, Trivedi S, Wang J, et al
    Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
    Cancer. 2017 Oct 20. doi: 10.1002/cncr.31063.
    PubMed     Abstract available


  31. NELSON RA, Lai LL
    Elevated risk of human papillomavirus-related second cancers in survivors of anal canal cancer.
    Cancer. 2017;123:4013-4021.
    PubMed     Abstract available


    September 2017
  32. DESHMUKH AA, Chiao EY, Cantor SB, Stier EA, et al
    Management of precancerous anal intraepithelial lesions in human immunodeficiency virus-positive men who have sex with men: Clinical effectiveness and cost-effectiveness.
    Cancer. 2017 Sep 26. doi: 10.1002/cncr.31035.
    PubMed     Abstract available


  33. SACCO AG, Cohen EE
    Serum antibodies open the door to prediction and prognostication in human papillomavirus-related head and neck cancer.
    Cancer. 2017 Sep 26. doi: 10.1002/cncr.30970.
    PubMed    


  34. TAO X, Austin RM, Zhang H, Zhang L, et al
    Histopathologic follow-up and HPV test results with HSIL Papanicolaou test results in China's largest academic women's hospital.
    Cancer. 2017 Sep 8. doi: 10.1002/cncy.21914.
    PubMed     Abstract available


  35. PRINJA S, Bahuguna P, Faujdar DS, Jyani G, et al
    Cost-effectiveness of human papillomavirus vaccination for adolescent girls in Punjab state: Implications for India's universal immunization program.
    Cancer. 2017;123:3253-3260.
    PubMed     Abstract available


    August 2017
  36. TRACHT JM, Davis AD, Fasciano DN, Eltoum IA, et al
    Discrepant HPV/cytology cotesting results: Are there differences between cytology-negative versus HPV-negative cervical intraepithelial neoplasia?
    Cancer. 2017 Aug 17. doi: 10.1002/cncy.21905.
    PubMed     Abstract available


    July 2017
  37. AN Y, Park HS, Kelly JR, Stahl JM, et al
    The prognostic value of extranodal extension in human papillomavirus-associated oropharyngeal squamous cell carcinoma.
    Cancer. 2017;123:2762-2772.
    PubMed     Abstract available


  38. CHANDRASEKHARAPPA SC, Chinn SB, Donovan FX, Chowdhury NI, et al
    Assessing the spectrum of germline variation in Fanconi anemia genes among patients with head and neck carcinoma before age 50.
    Cancer. 2017 Jul 5. doi: 10.1002/cncr.30802.
    PubMed     Abstract available


    June 2017
  39. GE Y, Christensen P, Luna E, Armylagos D, et al
    Performance of Aptima and Cobas HPV testing platforms in detecting high-grade cervical dysplasia and cancer.
    Cancer. 2017 Jun 2. doi: 10.1002/cncy.21875.
    PubMed     Abstract available


    May 2017
  40. MALM IJ, Fan CJ, Yin LX, Li DX, et al
    Evaluation of proposed staging systems for human papillomavirus-related oropharyngeal squamous cell carcinoma.
    Cancer. 2017;123:1768-1777.
    PubMed     Abstract available


  41. GUO M, Khanna A, Wang J, Dawlett MA, et al
    Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.
    Cancer. 2017 May 12. doi: 10.1002/cncy.21877.
    PubMed     Abstract available


  42. SMALL W JR, Bacon MA, Bajaj A, Chuang LT, et al
    Cervical cancer: A global health crisis.
    Cancer. 2017 May 2. doi: 10.1002/cncr.30667.
    PubMed     Abstract available


  43. PRINTZ C
    CDC recommends only 2 HPV doses for younger adolescents.
    Cancer. 2017;123:1485.
    PubMed    


  44. FAKHRY C, Westra WH, Wang SJ, van Zante A, et al
    The prognostic role of sex, race, and human papillomavirus in oropharyngeal and nonoropharyngeal head and neck squamous cell cancer.
    Cancer. 2017;123:1566-1575.
    PubMed     Abstract available


    April 2017
  45. ZUMSTEG ZS, Lok BH, Ho AS, Drill E, et al
    The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 years and older with oropharyngeal carcinoma in the intensity-modulated radiotherapy era.
    Cancer. 2017;123:1345-1353.
    PubMed     Abstract available


  46. ALSBEIH GA, Al-Harbi NM, Bin Judia SS, Khoja HA, et al
    Reduced rate of human papillomavirus infection and genetic overtransmission of TP53 72C polymorphic variant lower cervical cancer incidence.
    Cancer. 2017 Apr 10. doi: 10.1002/cncr.30635.
    PubMed     Abstract available


  47. D'SOUZA G, Robbins HA
    Sexual and relationship health among survivors of oropharyngeal or oral cavity squamous cell carcinoma.
    Cancer. 2017;123:1092-1094.
    PubMed    


    March 2017
  48. BERMAN TA, Schiller JT
    Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases.
    Cancer. 2017 Mar 27. doi: 10.1002/cncr.30588.
    PubMed     Abstract available


  49. HAJEK M, Sewell A, Kaech S, Burtness B, et al
    TRAF3/CYLD mutations identify a distinct subset of human papilloma virus-associated head and neck squamous cell carcinoma.
    Cancer. 2017 Mar 13. doi: 10.1002/cncr.30570.
    PubMed     Abstract available


  50. BENEVOLO M, Allia E, Gustinucci D, Rollo F, et al
    Interobserver reproducibility of cytologic p16INK4a /Ki-67 dual immunostaining in human papillomavirus-positive women.
    Cancer. 2017;125:212-220.
    PubMed     Abstract available


    February 2017
  51. BEADLE BM
    The impact of HPV testing for oropharyngeal cancers: Why the addendum matters.
    Cancer. 2017 Feb 27. doi: 10.1002/cncy.21842.
    PubMed    


  52. TABERNA M, Inglehart RC, Pickard RK, Fakhry C, et al
    Significant changes in sexual behavior after a diagnosis of human papillomavirus-positive and human papillomavirus-negative oral cancer.
    Cancer. 2017 Feb 14. doi: 10.1002/cncr.30564.
    PubMed     Abstract available


    January 2017
  53. SHER DJ, Rusthoven CG, Khan SA, Fidler MJ, et al
    National patterns of care and predictors of neoadjuvant and concurrent chemotherapy use with definitive radiotherapy in the treatment of patients with oropharyngeal squamous cell carcinoma.
    Cancer. 2017;123:273-282.
    PubMed     Abstract available


    December 2016
  54. OVESTAD IT, Dalen I, Hansen E, Loge JL, et al
    Clinical value of fully automated p16/Ki-67 dual staining in the triage of HPV-positive women in the Norwegian Cervical Cancer Screening Program.
    Cancer. 2016 Dec 5. doi: 10.1002/cncy.21807.
    PubMed     Abstract available


  55. BAUMAN JE, Cohen E, Ferris RL, Adelstein DJ, et al
    Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.
    Cancer. 2016 Dec 1. doi: 10.1002/cncr.30449.
    PubMed     Abstract available


    November 2016
  56. DE BROT L, Pellegrini B, Moretti ST, Carraro DM, et al
    Infections with multiple high-risk HPV types are associated with high-grade and persistent low-grade intraepithelial lesions of the cervix.
    Cancer. 2016 Nov 21. doi: 10.1002/cncy.21789.
    PubMed     Abstract available


    October 2016
  57. PATADJI S, Li Z, Pradhan D, Zhao C, et al
    Significance of high-risk HPV detection in women with atypical glandular cells on Pap testing: Analysis of 1857 cases from an academic institution.
    Cancer. 2016 Oct 24. doi: 10.1002/cncy.21791.
    PubMed     Abstract available


  58. DOXTADER EE, Brainard JA, Underwood D, Chute DJ, et al
    Knowledge of the HPV status biases cytotechnologists' interpretation of Pap tests originally diagnosed as negative for intraepithelial lesion or malignancy.
    Cancer. 2016 Oct 12. doi: 10.1002/cncy.21783.
    PubMed     Abstract available


    September 2016
  59. SILVER MI, Schiffman M, Fetterman B, Poitras NE, et al
    The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen.
    Cancer. 2016 Sep 22. doi: 10.1002/cncr.30277.
    PubMed     Abstract available


    August 2016
  60. MAZUL AL, Taylor JM, Divaris K, Weissler MC, et al
    Oral health and human papillomavirus-associated head and neck squamous cell carcinoma.
    Cancer. 2016 Aug 29. doi: 10.1002/cncr.30312.
    PubMed     Abstract available


  61. JIMENO A, Machiels JP, Wirth L, Specenier P, et al
    Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
    Cancer. 2016 Aug 15. doi: 10.1002/cncr.30256.
    PubMed     Abstract available


    July 2016
  62. BURGER EA, Lee K, Saraiya M, Thompson TD, et al
    Racial and ethnic disparities in human papillomavirus-associated cancer burden with first-generation and second-generation human papillomavirus vaccines.
    Cancer. 2016;122:2057-66.
    PubMed     Abstract available


  63. HORNE ZD, Glaser SM, Vargo JA, Ferris RL, et al
    Confirmation of proposed human papillomavirus risk-adapted staging according to AJCC/UICC TNM criteria for positive oropharyngeal carcinomas.
    Cancer. 2016;122:2021-30.
    PubMed     Abstract available


    June 2016
  64. GARDEN AS, Fuller CD, Rosenthal DI, William WN Jr, et al
    Radiation therapy (with or without neck surgery) for phenotypic human papillomavirus-associated oropharyngeal cancer.
    Cancer. 2016;122:1702-7.
    PubMed     Abstract available


    May 2016
  65. BISHOP JA, Ha PK
    Human papillomavirus detection in a "Digital" age.
    Cancer. 2016;122:1502-4.
    PubMed    


  66. BIRON VL, Kostiuk M, Isaac A, Puttagunta L, et al
    Detection of human papillomavirus type 16 in oropharyngeal squamous cell carcinoma using droplet digital polymerase chain reaction.
    Cancer. 2016;122:1544-51.
    PubMed     Abstract available


  67. CRACCHIOLO JR, Baxi SS, Morris LG, Ganly I, et al
    Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: National Cancer Data Base.
    Cancer. 2016;122:1523-32.
    PubMed     Abstract available


  68. PATEL MA, Blackford AL, Rettig EM, Richmon JD, et al
    Rising population of survivors of oral squamous cell cancer in the United States.
    Cancer. 2016;122:1380-7.
    PubMed     Abstract available


  69. REUSCHENBACH M, Pauligk C, Karbach J, Rafiyan MR, et al
    A phase 1/2a study to test the safety and immunogenicity of a p16(INK4a) peptide vaccine in patients with advanced human papillomavirus-associated cancers.
    Cancer. 2016;122:1425-33.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Sexually Transmitted Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: